Los Angeles Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$251K Buy
96,925
+96,298
+15,359% +$285K ﹤0.01% 1104
2026
Q1
$1.93K Hold
627
﹤0.01% 2292
2025
Q4
$5.04K Buy
+627
New +$3.84K ﹤0.01% 2279
2024
Q3
Sell
-22,077
Closed -$93.2K 1173
2024
Q2
$93.2K Sell
22,077
-65,854
-75% -$266K ﹤0.01% 1153
2024
Q1
$448K Buy
87,931
+29,844
+51% +$168K ﹤0.01% 909
2023
Q4
$541K Buy
58,087
+37,867
+187% +$261K ﹤0.01% 847
2023
Q3
$132K Buy
+20,220
New +$161K ﹤0.01% 1083
2022
Q4
Sell
-14,599
Closed -$151K 1191
2022
Q3
$151K Buy
+14,599
New +$154K ﹤0.01% 1191

Other funds holding AVXL

Los Angeles Capital Management's AVXL Position: Q2 2026 in Review

Los Angeles Capital Management increased its Anavex Life Sciences (AVXL) stake by 15,359% in Q2 2026, buying an estimated $285K and bringing the position to 96,925 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #1104.

Los Angeles Capital Management first reported a position in AVXL in Q3 2022 and has held it in 8 quarters since. The position peaked at $541K in Q4 2023. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Los Angeles Capital Management held 96,925 shares of Anavex Life Sciences worth $251K as of Q2 2026.
  • Los Angeles Capital Management bought 96,298 Anavex Life Sciences shares in Q2 2026, an estimated $285K.
  • Anavex Life Sciences made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1104 holding.
  • Los Angeles Capital Management first reported a position in Anavex Life Sciences in Q3 2022 and has held it in 8 quarters since.
  • Los Angeles Capital Management's Anavex Life Sciences position peaked at $541K in Q4 2023.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.